Invesco Ltd. Denali Therapeutics Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Invesco Ltd. holds 206,363 shares of DNLI stock, worth $5.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

206,363

Previous 116,232 77.54%

Holding current value

$5.17 Million

Previous $2.7 Million 122.79%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$20.96 - $31.05 $1.89 Million - $2.8 Million	90,131 Added 77.54%	206,363 $6.01 Million
Q2 2024 Aug 13, 2024	BUY	$14.96 - $23.22 $27,376 - $42,492	1,830 Added 1.6%	116,232 $2.7 Million
Q1 2024 May 14, 2024	BUY	$15.83 - $23.35 $558,213 - $823,391	35,263 Added 44.56%	114,402 $2.35 Million
Q4 2023 Feb 12, 2024	SELL	$16.2 - $23.18 $149,266 - $213,580	-9,214 Reduced 10.43%	79,139 $1.7 Million
Q3 2023 Nov 13, 2023	SELL	$20.63 - $30.17 $94,237 - $137,816	-4,568 Reduced 4.92%	88,353 $1.82 Million
Q2 2023 Aug 11, 2023	BUY	$23.37 - $32.96 $233,326 - $329,072	9,984 Added 12.04%	92,921 $2.74 Million
Q1 2023 May 12, 2023	SELL	$21.91 - $32.67 $127,121 - $189,551	-5,802 Reduced 6.54%	82,937 $1.91 Million
Q4 2022 Feb 13, 2023	BUY	$26.28 - $33.92 $284,980 - $367,828	10,844 Added 13.92%	88,739 $2.47 Million
Q3 2022 Nov 14, 2022	BUY	$25.97 - $38.53 $109,827 - $162,943	4,229 Added 5.74%	77,895 $2.39 Million
Q2 2022 Aug 15, 2022	BUY	$20.88 - $35.19 $125,948 - $212,266	6,032 Added 8.92%	73,666 $2.17 Million
Q1 2022 May 16, 2022	BUY	$29.0 - $47.27 $671,930 - $1.1 Million	23,170 Added 52.11%	67,634 $2.18 Million
Q4 2021 Feb 14, 2022	SELL	$42.59 - $55.02 $159,882 - $206,545	-3,754 Reduced 7.79%	44,464 $1.98 Million
Q3 2021 Nov 15, 2021	SELL	$48.48 - $78.23 $16.3 Million - $26.2 Million	-335,347 Reduced 87.43%	48,218 $2.43 Million
Q2 2021 Aug 17, 2021	BUY	$50.3 - $78.44 $18 Million - $28 Million	356,912 Added 1339.11%	383,565 $30.1 Million
Q1 2021 May 17, 2021	SELL	$53.8 - $81.53 $10 Million - $15.2 Million	-185,922 Reduced 87.46%	26,653 $1.52 Million
Q4 2020 Feb 16, 2021	SELL	$36.89 - $93.56 $3.76 Million - $9.53 Million	-101,824 Reduced 32.39%	212,575 $17.8 Million
Q3 2020 Nov 16, 2020	BUY	$23.13 - $38.84 $573,253 - $962,610	24,784 Added 8.56%	314,399 $11.3 Million
Q2 2020 Aug 14, 2020	SELL	$16.01 - $28.82 $9,445 - $17,003	-590 Reduced 0.2%	289,615 $7 Million
Q1 2020 May 15, 2020	BUY	$14.2 - $27.98 $1.42 Million - $2.79 Million	99,697 Added 52.33%	290,205 $5.08 Million
Q4 2019 Feb 14, 2020	SELL	$14.4 - $19.99 $9,057 - $12,573	-629 Reduced 0.33%	190,508 $3.32 Million
Q3 2019 Nov 14, 2019	BUY	$15.32 - $21.92 $1.1 Million - $1.57 Million	71,540 Added 59.82%	191,137 $2.93 Million
Q2 2019 Aug 14, 2019	SELL	$18.5 - $28.14 $25,789 - $39,227	-1,394 Reduced 1.15%	119,597 $2.48 Million
Q1 2019 May 15, 2019	SELL	$17.99 - $24.65 $806,761 - $1.11 Million	-44,845 Reduced 27.04%	120,991 $2.81 Million
Q4 2018 Feb 14, 2019	BUY	$13.88 - $21.75 $2.3 Million - $3.61 Million	165,836 New	165,836 $3.43 Million

Others Institutions Holding DNLI

# of Institutions

228

Shares Held

120M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.36B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account